Cargando…

Combination of JAK2 and HSP90 inhibitors: an effective therapeutic option in drug-resistant chronic myelogenous leukemia

Recent studies suggest that JAK2 serves as a novel therapeutic target in Bcr-Abl+ chronic myelogenous leukemia (CML). We have reported the existence of an HSP90- associated high molecular weight network complex (HMWNC) that is composed of HSP90 client proteins BCR-ABL, JAK2, and STAT3 in wild type B...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chakraborty, Sandip N., Leng, Xiaohong, Perazzona, Bastianella, Sun, Xiaoping, Lin, Yu-Hsi, Arlinghaus, Ralph B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979592/ https://www.ncbi.nlm.nih.gov/pubmed/27551334 http://dx.doi.org/10.18632/genesandcancer.111

Ejemplares similares

HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells
por: Tao, Wenjing, et al.
Publicado: (2015)

Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase
por: Chakraborty, S, et al.
Publicado: (2013)

Janus kinase 2 regulates Bcr–Abl signaling in chronic myeloid leukemia
por: Samanta, A, et al.
Publicado: (2011)

The interplay between inhibition of JAK2 and HSP90
por: Fridman, Jordan S., et al.
Publicado: (2012)

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
por: Weigert, Oliver, et al.
Publicado: (2012)

Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia
por: Khajapeer, Kalubai Vari, et al.
Publicado: (2015)

Modulation of Akt and ERK1/2 Pathways by Resveratrol in Chronic Myelogenous Leukemia (CML) Cells Results in the Downregulation of Hsp70
por: Banerjee Mustafi, Soumyajit, et al.
Publicado: (2010)

HSP90 is essential for Jak-STAT signaling in classical Hodgkin lymphoma cells
por: Schoof, Nils, et al.
Publicado: (2009)

Omacetaxine Mepesuccinate: A New Treatment Option for Patients With Chronic Myelogenous Leukemia
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Therapeutic and diagnostic implications of Hsp90 activation
por: Kamal, Adeela, et al.
Publicado: (2004)

Heat Shock Protein 90 (Hsp90) and Hsp70 as Potential Therapeutic Targets in Autoimmune Skin Diseases
por: Tukaj, Stefan, et al.
Publicado: (2022)

Chronic myelogenous leukemia in Libya
por: Mehdi, Itrat, et al.
Publicado: (2012)

Chronic myelogenous leukemia on target
por: Némethová, Veronika, et al.
Publicado: (2018)

Inhibitors of HSP90 in melanoma
por: Mielczarek-Lewandowska, Aleksandra, et al.
Publicado: (2019)

Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
por: Proia, David A., et al.
Publicado: (2011)

Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1
por: Park, Hye-Kyung, et al.
Publicado: (2020)

Flavivirus Nonstructural Protein NS5 Dysregulates HSP90 to Broadly Inhibit JAK/STAT Signaling
por: Roby, Justin A., et al.
Publicado: (2020)

HSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative Neoplasms
por: Sevin, Margaux, et al.
Publicado: (2015)

Chronic myelogenous leukemia in ulcerative colitis
por: Katsanos, Konstantinos H., et al.
Publicado: (2011)

Chronic Myelogenous Leukemia (CML) in the elderly
por: Balducci, Lodovico, et al.
Publicado: (2014)

Bosutinib in the management of chronic myelogenous leukemia
por: Amsberg, Gunhild Keller-von, et al.
Publicado: (2013)

Atypical Presentation of Chronic Myelogenous Leukemia
por: Updyke, Katelyn Mariko, et al.
Publicado: (2017)

Acute Myelogenous Leukemia and Febrile Neutropenia
por: Herbers, Alexandra, et al.
Publicado: (2009)

LYPD3, a New Biomarker and Therapeutic Target for Acute Myelogenous Leukemia
por: Hu, Tingting, et al.
Publicado: (2022)

Molecular Chaperone Hsp90 Is a Therapeutic Target for Noroviruses
por: Vashist, Surender, et al.
Publicado: (2015)

Hsp90 Inhibition: A Promising Therapeutic Approach for ARSACS
por: Nethisinghe, Suran, et al.
Publicado: (2021)

Hsp90 in Human Diseases: Molecular Mechanisms to Therapeutic Approaches
por: Sumi, Mamta P., et al.
Publicado: (2022)

HSP90 inhibitors disrupt a transient HSP90-HSF1 interaction and identify a noncanonical model of HSP90-mediated HSF1 regulation
por: Kijima, Toshiki, et al.
Publicado: (2018)

The Chaperone System in Breast Cancer: Roles and Therapeutic Prospects of the Molecular Chaperones Hsp27, Hsp60, Hsp70, and Hsp90
por: Alberti, Giusi, et al.
Publicado: (2022)

Unusual Case of Simultaneous Presentation of Plasma Cell Myeloma, Chronic Myelogenous Leukemia, and a Jak2 Positive Myeloproliferative Disorder
por: Maerki, J., et al.
Publicado: (2014)

Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
por: Mumin, Nuramalina H., et al.
Publicado: (2019)

Circulating heat shock protein 90 (Hsp90) and autoantibodies to Hsp90 are increased in patients with atopic dermatitis
por: Sitko, Krzysztof, et al.
Publicado: (2021)

Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo
por: Wang, Wenqian, et al.
Publicado: (2016)

Hsp90 Inhibitors Prevent HSV-1 Replication by Directly Targeting UL42-Hsp90 Complex
por: Qin, Shurong, et al.
Publicado: (2022)

A Mitochondrial-targeted purine-based HSP90 antagonist for leukemia therapy
por: Bryant, Kelly G., et al.
Publicado: (2017)

Applications of Microarray Technology to Acute Myelogenous Leukemia
por: Goswami, Rashmi S., et al.
Publicado: (2008)

Biomarkers for determining the prognosis in chronic myelogenous leukemia
por: Sweet, Kendra, et al.
Publicado: (2013)

Supremacy of nanoparticles in the therapy of chronic myelogenous leukemia
por: Janani, Gopalarethinam, et al.
Publicado: (2023)

Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy
por: Xu, Zhenshu, et al.
Publicado: (2009)

Hsp-90 and the biology of nematodes
por: Him, Nik AIIN, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ihs4r17orvkh9fl0q5lv8antp7